Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | HTR2C | P28335 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | HTR1D | P28221 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | BRCA1 | P38398 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | JAK2 | O60674 | 1/20 | 0.63 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.63 |
| ▸ | MARK3 | P27448 | 1/20 | 0.63 |
| ▸ | PRKCI | P41743 | 1/20 | 0.63 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.63 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.63 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ru-24969 SCHEMBL29390076 | 1.00 | HTR6 (1.00) | HTR6KDM4EALDH1A1MAPTHTR2C | |
| Ru-24969 SCHEMBL29550112 | 0.90 | HTR6 (0.81) | HTR6KDM4EALDH1A1MAPTHTR2C | |
| SCHEMBL7864917 | 0.90 | HTR6 (0.81) | HTR6KDM4EALDH1A1MAPTHTR2C | |
| SCHEMBL6631651 | 0.82 | KDM4E (0.70) | HTR6KDM4EALDH1A1MAPTHTR2C | |
| SCHEMBL8925573 | 0.82 | HTR1D (0.69) | HTR6KDM4EALDH1A1MAPTHTR2C | |
| SCHEMBL5705100 | 0.80 | KDM4E (0.66) | HTR6KDM4EALDH1A1MAPTHTR2C | |
| SCHEMBL7460028 | 0.80 | HTR6 (0.67) | HTR6KDM4EALDH1A1MAPTHTR2C | |
| SCHEMBL3836149 | 0.80 | HTR6 (0.67) | HTR6KDM4EALDH1A1MAPTHTR2C | |
| SCHEMBL1675799 | 0.80 | HTR6 (0.67) | HTR6KDM4EALDH1A1MAPTHTR2C | |
| SCHEMBL2783986 | 0.80 | HTR6 (0.67) | HTR6KDM4EALDH1A1MAPTHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS INC (US) | 2025-09-25 | — | — | US | claimed |
| WO-2023212244-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | claimed |
| US-20220249440-A1 | MUSCLE REGENERATION PROMOTER | SATO PHARMACEUTICAL CO., LTD. (JP) | 2022-08-11 | — | — | US | claimed |
| US-20140350064-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF | ALS MOUNTAIN LLC | 2014-11-27 | — | — | US | claimed |
| US-20120183600-A1 | NOVEL COMPOSITION FOR TREATING METABOLIC SYNDROME AND OTHER CONDITIONS | CHEN CHIEN-HUNG (US) | 2012-07-19 | — | — | US | claimed |
| US-20050080084-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of central nervous system damage | PHARMACIA CORPORATION | 2005-04-14 | — | — | US | claimed |
| EP-0455510-B1 | Use of 5-HT1A receptor agonist compounds for inhibiting gastric acid secretion | LILLY CO ELI (US) | 1996-11-27 | — | — | EP | claimed |
| EP-0455510-A2 | Use of 5-HT1A receptor agonist compounds for inhibiting gastric acid secretion | ELI LILLY AND COMPANY (US) | 1991-11-06 | — | — | EP | claimed |
| US-4196209-A | Treating psychic disorders with piperidyl-indoles | ROUSSEL UCLAF (FR) | 1980-04-01 | — | — | US | claimed |
| JP-8027029-A | — | — | None | — | — | JP | disclosed |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS INC (US) | 2025-09-25 | — | — | US | disclosed |
| US-20250034106-A1 | 3-CYCLOAMINO-INDOLE COMPOUNDS AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | MINDSET PHARMA INC. (CA) | 2025-01-30 | — | — | US | disclosed |
| US-20240376052-A1 | N-SUBSTITUTED INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | MINDSET PHARMA INC. (CA) | 2024-11-14 | — | — | US | disclosed |
| WO-2023212244-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| EP-0379314-A1 | 3-(1,2,5,6-Tetrahydropyridyl)-pyrrolopyridines | PFIZER INC. (US) | 1990-07-25 | — | — | EP | disclosed |
| EP-0360077-A2 | Use of serotonin antagonists in the treatment of apoplexia cerebri | Troponwerke GmbH & Co. KG (DE) | 1990-03-28 | — | — | EP | disclosed |
| US-4855302-A | 8-((4-(INDOL-3-YL)PIPERIDINO)ALKYL)-8-AZASPIRO(4.5)DECANE-7,9 -DIONES | ROUSSEL UCLAF (FR) | 1989-08-08 | — | — | US | disclosed |
| US-4278677-A | Tetrahydropyridinyl indoles | ROUSSEL UCLAF (FR) | 1981-07-14 | — | — | US | disclosed |
| US-4232031-A | Process for preparation of piperidyl-indoles | ROUSSEL UCLAF (FR) | 1980-11-04 | — | — | US | disclosed |
| US-4196209-A | Treating psychic disorders with piperidyl-indoles | ROUSSEL UCLAF (FR) | 1980-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240376052-A1 | N-SUBSTITUTED INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | TPH1, HTR5A, TPH2 | HTR6 6/4885KDM4E 3293/4885ALDH1A1 1436/4885 |
| US-20220249440-A1 | MUSCLE REGENERATION PROMOTER | MUSK, MYLK2, MYH2 | HTR6 62/4885KDM4E 1326/4885ALDH1A1 1317/4885 |
| US-20050080084-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of central nervous system damage | TPH2, TPH1, HTR2A | HTR6 11/4885KDM4E 4399/4885ALDH1A1 1946/4885 |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | HTR2A, HTR5A, HTR6 | HTR6 3/4885KDM4E 4347/4885ALDH1A1 913/4885 |
| US-20250034106-A1 | 3-CYCLOAMINO-INDOLE COMPOUNDS AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | TPH1, HTR3A, HTR1A | HTR6 6/4885KDM4E 3948/4885ALDH1A1 1854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.